CM
RARE icon

Caption Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Caption Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24M Buy
718,800
+428,800
+148% +$10.7M 0.11% 191
2026
Q1 		$6.08M Sell
290,000
-114,700
-28% -$2.58M 0.04% 476
2025
Q4 		$9.31M Buy
404,700
+254,900
+170% +$8.38M 0.06% 350
2025
Q3 		$4.51M Sell
149,800
-343,700
-70% -$10.3M 0.04% 527
2025
Q2 		$17.9M Buy
493,500
+196,500
+66% +$7.08M 0.2% 102
2025
Q1 		$10.8M Buy
297,000
+94,500
+47% +$3.93M 0.1% 189
2024
Q4 		$8.52M Buy
202,500
+172,500
+575% +$8.56M 0.08% 234
2024
Q3 		$1.67M Buy
+30,000
New +$1.53M 0.03% 628
2024
Q2 		– Sell
-23,600
Closed -$1.1M – 1442
2024
Q1 		$1.1M Sell
23,600
-6,400
-21% -$302K 0.02% 705
2023
Q4 		$1.43M Buy
30,000
+7,500
+33% +$291K 0.02% 710
2023
Q3 		$802K Sell
22,500
-67,500
-75% -$2.67M 0.01% 830
2023
Q2 		$4.15M Buy
90,000
+60,000
+200% +$2.78M 0.07% 324
2023
Q1 		$1.2M Buy
30,000
+10,000
+50% +$429K 0.02% 591
2022
Q4 		$927K Sell
20,000
-62,400
-76% -$2.45M 0.01% 770
2022
Q3 		$3.41M Sell
82,400
-80,200
-49% -$4.12M 0.05% 472
2022
Q2 		$9.7M Buy
162,600
+129,100
+385% +$7.94M 0.13% 196
2022
Q1 		$2.43M Buy
+33,500
New +$2.33M 0.03% 684
2021
Q2 		– Sell
-25,000
Closed -$2.85M – 1522
2021
Q1 		$2.85M Buy
+25,000
New +$3.4M 0.06% 413
2020
Q4 		– Sell
-27,000
Closed -$2.22M – 1202
2020
Q3 		$2.22M Sell
27,000
-29,500
-52% -$2.45M 0.05% 399
2020
Q2 		$4.42M Buy
+56,500
New +$3.74M 0.15% 191

Other funds holding RARE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Caption Management's RARE Position: Q2 2026 in Review

Caption Management increased its Ultragenyx Pharmaceutical (RARE) stake by 18% in Q2 2026, buying an estimated $497K and bringing the position to 130,000 shares worth $4.34M. The position accounts for 0.02% of the portfolio, ranked #628.

Caption Management first reported a position in RARE in Q1 2021 and has held it in 13 quarters since. The position peaked at $8.64M in Q2 2025. 311 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

  • Caption Management held 130,000 shares of Ultragenyx Pharmaceutical worth $4.34M as of Q2 2026.
  • Caption Management bought 20,000 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $497K.
  • Ultragenyx Pharmaceutical made up 0.02% of Caption Management's portfolio in Q2 2026, its #628 holding.
  • Caption Management first reported a position in Ultragenyx Pharmaceutical in Q1 2021 and has held it in 13 quarters since.
  • Caption Management's Ultragenyx Pharmaceutical position peaked at $8.64M in Q2 2025.
  • 311 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Caption Management's 13F filing for Q2 2026, filed 14 Aug 2026.